Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Francesca Romana Ponziani; Antonio Gasbarrini

doi:10.1111/liv.13052

Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Francesca Romana Ponziani, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivista › Articolo

16 Citazioni (Scopus)

Abstract

Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Rivista	Liver International
Numero di pubblicazione	Dicembre
DOI	https://doi.org/10.1111/liv.13052
Stato di pubblicazione	Pubblicato - 2015

All Science Journal Classification (ASJC) codes

Epatologia

Keywords

adverse events
hepatocellular carcinoma
sorafenib
tolerable adverse events protocol
toxicity
tumor response

Accesso al documento

10.1111/liv.13052

Altri file e collegamenti

Cita questo

@article{ac13791010ee4f6f96c7cef9cd48ca42,

title = "Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma",

abstract = "Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.",

keywords = "adverse events, hepatocellular carcinoma, sorafenib, tolerable adverse events protocol, toxicity, tumor response, adverse events, hepatocellular carcinoma, sorafenib, tolerable adverse events protocol, toxicity, tumor response",

author = "Ponziani, \{Francesca Romana\} and Antonio Gasbarrini",

year = "2015",

doi = "10.1111/liv.13052",

language = "English",

pages = "N/A--N/A",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "Dicembre",

}

TY - JOUR

T1 - Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

AU - Ponziani, Francesca Romana

AU - Gasbarrini, Antonio

PY - 2015

Y1 - 2015

N2 - Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.

AB - Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.

KW - adverse events

KW - hepatocellular carcinoma

KW - sorafenib

KW - tolerable adverse events protocol

KW - toxicity

KW - tumor response

KW - adverse events

KW - hepatocellular carcinoma

KW - sorafenib

KW - tolerable adverse events protocol

KW - toxicity

KW - tumor response

UR - https://publicatt.unicatt.it/handle/10807/70768

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84979600113&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84979600113&origin=inward

U2 - 10.1111/liv.13052

DO - 10.1111/liv.13052

M3 - Article

SN - 1478-3223

SP - N/A-N/A

JO - Liver International

JF - Liver International

IS - Dicembre

ER -

Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo